Along similar lines, a prospective phase 2 randomized clinical trial was conducted to evaluate and compare the efficacy of a combination of metformin and EGFR-TKIs with EGFR-TKIs alone in stage IIIB-IV lung adenocarcinoma patients harboring an activating EGFR mutation [98]. Here, EGFR is linked to lung adenocarcinoma.